Literature DB >> 9447835

The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma.

F Silvestri1, G Barillari, R Fanin, C Pipan, E Falasca, F Salmaso, F Zaja, L Infanti, F Patriarca, G A Botta, M Baccarani.   

Abstract

Increasing evidence suggests that the hepatitis C virus (HCV) might be involved in the pathogenesis of B cell non-Hodgkin's lymphomas (NHL). Since several HCV genotypes are currently identifiable and might be involved in the pathogenesis of different diseases (with different severity and responsiveness to therapy), the aim of our study was to assess the prevalence of viral genotypes in a group of patients with HCV-related NHL. Among 470 consecutive patients, 42 HCV Ab-positive cases were identified. HCV RNA could be detected by reverse transcriptase-polymerase chain reaction and genotyping performed in 31 of these cases. As compared to our control group (211 healthy blood donors and patients with chronic liver disease), a striking high prevalence of genotype 2ac was detected among B cell NHL (48.4 vs 9.0%), with a relative risk of infection of 5.37 (P < 0.0001). No major differences were observed in the distribution of NHL histotypes and in the clinical features among patients with genotype 1b (the other most frequent genotype) or 2ac, a part from a trend towards a higher percentage of liver disease and a lower likelihood of response to interferon for patients with genotype 1b. The same high prevalence of genotype 2ac has been recently reported in patients with mixed cryoglobulinemia (MC), monoclonal gammopathies, B cell NHL complicating MC and autoimmune hepatitis. All these data taken together suggest that genotype 2ac might be involved in the pathogenesis of lymphoproliferative and autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9447835     DOI: 10.1038/sj.leu.2400869

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

Review 1.  Hepatitis C virus infection and lymphoproliferative disorders.

Authors:  L R Peña; S Nand; N De Maria; D H Van Thiel
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

2.  Tumor-initiating stem-like cells and drug resistance: carcinogenesis through Toll-like receptors, environmental factors, and virus.

Authors:  Keigo Machida
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

Review 3.  Hepatitis C infection and lymphoproliferative disease: accidental comorbidities?

Authors:  Tawfik Khoury; Shmuel Chen; Tomer Adar; E Ollech Jacob; Meir Mizrahi
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

4.  Repeat hepatectomies for hepatic malignant lymphoma and hepatocellular carcinoma associated with chronic hepatitis C: report of a case.

Authors:  Hirotada Tajiri; Keishi Sugimachi; Nao Kinjo; Masahiko Ikebe; Junko Tanaka; Kiyoshi Tanaka; Shuichi Tsukamoto; Shinsuke Mii; Eiji Kajiwara; Tatsuro Shimokama; Hidefumi Higashi
Journal:  Surg Today       Date:  2013-02-13       Impact factor: 2.549

Review 5.  Hepatitis c and lymphoma.

Authors:  F Silvestri; A Sperotto; R Fanin
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.945

6.  Virus-associated lymphomagenesis.

Authors:  V Z Tarantul
Journal:  Int J Biomed Sci       Date:  2006-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.